Abstract: A method of operating a nuclear reactor reduces the number of reload fuels to be loaded into the nuclear reactor in the second and the following operation cycles. The nuclear reactor has a reactor core in which a plurality of reload fuel assemblies respectively having different infinite multiplication factors are arranged. The method operates the nuclear reactor with control rods inserted in control cells each comprising four reload fuel assemblies having relatively large infinite multiplication factors among the plurality of reload fuel assemblies for a period longer than half of a period of an operation cycle.

Abstract: Several unit loading patterns are arranged in the central area of an initial core to which the present invention is applied. The unit loading pattern is composed of one square-shaped unit cell and four cross-shaped control rods 3 which surround the unit cell. The unit cell is composed of one low enrichment fuel assembly 7, two high enrichment fuel assemblies 8 and one high enrichment fuel assembly 9. The low enrichment fuel assemblies 7 of each unit loading pattern adjoin each other and are arranged to constitute the first control cell 2a being square-shaped. The high enrichment fuel assemblies 9, obliquely adjoining the low enrichment fuel assembly 7 in each unit loading pattern, adjoin each other and are arranged to constitute the second control cell 2b being square-shaped.

Abstract: In an arrangement of an initial core, the core is loaded with 572 high enrichment fuel assemblies H with 4.2 wt % average enrichment and 300 low enrichment fuel assemblies L with 1.5 wt % average enrichment. The average enrichment of the core is about 3.3 wt %. In this core, only the low enrichment fuel assemblies are loaded into the most outer position of the core and the high enrichment fuel assemblies are loaded into an area other than the most outer position. In this arrangement, the average enrichment of reload fuel assemblies is 3.7 wt %.

Abstract: In a fuel loading method of the present invention, a nuclear reactor is operated up to the second cycle without exchanging the fuel. Low-enrichment fuel is discharged from a core at the end of the second cycle and at the end of the third cycle. Moreover, high-enrichment fuel with an average enrichment higher than that of replacement fuel is discharged from the core at the end of the third cycle and reloaded into the core at the end of the fifth cycle.According to the present invention, because the high-enrichment fuel discharged from the core at the end of the third cycle normally has a high enrichment, a short combustion period, and a low burnup compared to the replacement fuel burned for 4 to 5 cycles, a lot of fissionable material are left in the high-enrichment fuel. By reloading the high-enrichment fuel to the core after one cycle or more passes, it is possible to greatly increase the discharge exposure of initially loaded fuel.

Abstract: In an initial core of the present invention, a low enrichment fuel assembly having the lowest average enrichment factor and three fuel assemblies having a higher average enrichment factor than that of the low enrichment fuel assembly are arranged in a square shape, control rods of a cross shape are arranged at each of four corners of the square shape to constitute a unit loading pattern, and a plurality of the unit loading patterns are provided in the central region of the core, the fuel assemblies having the higher average enrichment factor are divided by a diagonal line into a first region of the side of the control rods and a second region of the side opposite to the control rods, and the number of the gadolinia-containing fuel rods is greater in the second region by at least two than in the first region.

Abstract: The present invention first provides monoclonal antibodies recognizing membrane phospholipase A.sub.2, namely, monoclonal antibodies PL-49, PL-71, PL-76, and PL-78, hybridomas producing them, methods for producing them, and immunoassays of membrane phospholipase A.sub.2 using them.The immunoassay of PLA.sub.2 M is useful for the diagnosis of articular rheumatism, cancers, and a wide variety of inflammatory states.